Phosphate Binders

Distinct Phosphate Targets Feasible, Pilot Study Shows

Distinct Phosphate Targets Feasible, Pilot Study Shows

By

A randomized controlled pilot study demonstrated the feasibility and safety of performing a large clinical trial that is powered to establish whether phosphate lowering reduces fatal and nonfatal cardiovascular events.

Sevelamer Carbonate Improves Pediatric Hyperphosphatemia

Sevelamer Carbonate Improves Pediatric Hyperphosphatemia

By

Phase 2 randomized placebo-controlled trial demonstrated the safety and efficacy of sevelamer in lowering serum phosphorus levels in children and adolescents.

Researchers: Iron-based Binders Best for Hyperphosphatemia

Researchers: Iron-based Binders Best for Hyperphosphatemia

By

Of 7 phosphate binders, iron-based agents were optimal when efficacy and safety are considered.

Iron-based Binder Improves Phosphorus Levels in Dialysis Patients

Iron-based Binder Improves Phosphorus Levels in Dialysis Patients

By

The proportion of patients with serum phosphorus levels within target range rose from 22% to 65% within 6 months of starting ferric citrate treatment.

Add-on Sevelamer Therapy May Improve Hemodialysis Patient Survival

Add-on Sevelamer Therapy May Improve Hemodialysis Patient Survival

By

Use of sevelamer was associated with a 14% decreased risk of death compared with non-use.

Education Can Improve Phosphate Control

Education Can Improve Phosphate Control

By

Patients receiving educational or behavioral interventions aimed at controlling hyperphosphatemia had an average reduction in phosphate of 0.23 mmol/L more than standard care patients.

Anemia Indication Sought for Phosphate Binder

Anemia Indication Sought for Phosphate Binder

By

Company asks FDA to approve ferric citrate for iron deficiency anemia in patients with non-dialysis dependent chronic kidney disease.

Study: Phosphate Binders Do Not Lower Death Risk

Study: Phosphate Binders Do Not Lower Death Risk

By

Calcium-based binders, however, are associated with greater odds of all-cause mortality versus sevelamer.

Uncontrolled Phosphorus Linked to Poor Binder Adherence

Uncontrolled Phosphorus Linked to Poor Binder Adherence

By

In a study, 61% of hemodialysis patients reported accidentally forgetting to take their medication or otherwise skipping doses unintentionally.

Sucroferric Oxyhydroxide Exhibits a Dose-Dependent Effect

Sucroferric Oxyhydroxide Exhibits a Dose-Dependent Effect

By

The phosphate binder is a useful treatment for hyperphosphatemia with a relatively low pill burden, researchers say.

Even High-Normal Phosphorus May Be an ESRD Risk Factor, Study Finds

Even High-Normal Phosphorus May Be an ESRD Risk Factor, Study Finds

By

Phosphorus targets in patients with chronic kidney disease stage 3 to 4 should be below 4.3 mg/dL, researchers report.

Young Patients Often Misperceive Adherence to Phosphorus Control

Young Patients Often Misperceive Adherence to Phosphorus Control

By

Hyperphosphatemia is present in many who say following diets and binder schedules is easy.

Patient Autonomy May Improve Phosphate Binder Adherence

Patient Autonomy May Improve Phosphate Binder Adherence

By

Autonomy support could be an appropriate target for culturally informed strategies to optimize mineral bone health.

Calcium-based Phosphate Binders Linked to Higher Mortality

Calcium-based Phosphate Binders Linked to Higher Mortality

By

A mortality rate increase of 43 cases per 1000 patients was found for calcium-based phosphate binders.

Iron-Based Binder Found to Improve Phosphorus Control, Cut Pill Burden

Iron-Based Binder Found to Improve Phosphorus Control, Cut Pill Burden

By

Researchers observe an 81% increase in dialysis patients achieving recommended phosphorus levels after switching to sucroferric oxyhydroxide.

Fixed-Dose Phosphate Binder Schedules May Be Less Than Ideal

Fixed-Dose Phosphate Binder Schedules May Be Less Than Ideal

By

Study of peritoneal dialysis patients showed that they do not adjust binders to match the phosphate content of meals and snacks.

Individual Variability Overlooked in Uncontrolled Hyperphosphatemia

Individual Variability Overlooked in Uncontrolled Hyperphosphatemia

By

Expert suggests factors beyond poor adherence to a low phosphorus diet and binder therapy may contribute to hyperphosphatemia.

Phosphate Binders Show Similar Efficacy in African Americans

Phosphate Binders Show Similar Efficacy in African Americans

By

Study compared sucroferric oxyhydroxide and sevelamer carbonate.

Nocturnal Dialysis Linked with Reduced Left Ventricular Mass

Nocturnal Dialysis Linked with Reduced Left Ventricular Mass

By

Recipients of in-hospital nighttime dialysis experienced a 14.2 gram reduction in left ventricle thickening.

Abnormal Mineral, Bone Markers in Dialysis Patients Hike Mortality

Abnormal Mineral, Bone Markers in Dialysis Patients Hike Mortality

By

Large European study identifies ranges of phosphorus, calcium, and parathyroid hormone levels with the lowest death risk.

Phosphate Binder Adherence Challenging for Dialysis Patients

Phosphate Binder Adherence Challenging for Dialysis Patients

By

In a study, 45% of hemodialysis patients internationally reported skipping phosphate binder pills at least once in the prior month.

Coaching and Financial Incentives May Reduce Phosphorus

Coaching and Financial Incentives May Reduce Phosphorus

By

Patients with hyperphosphatemia lowered their phosphorus levels with a dietitian's guidance or cash incentive.

Chronic Kidney Disease Raises Fracture Risk in Children

Chronic Kidney Disease Raises Fracture Risk in Children

By

Fracture rates are 2.4- to 3-fold higher than rates found in the general population of children and adolescents.

Iron-Based Binder Could Improve Adherence

Iron-Based Binder Could Improve Adherence

By

It had a phosphorus-lowering effect similar to that of sevelamer, but had a lower pill burden.

Non-Dialysis CKD-MBD Care Suboptimal

Non-Dialysis CKD-MBD Care Suboptimal

By

One-third of patients who missed clinical targets for phosphorus, calcium and/or parathormone remained untreated.

Raising Lanthanum Dose Cuts Phosphorus Levels

By

PARIS—Raising the dose of the calcium-free phosphate binder lanthanum carbonate from a lower conventionally used dose of 2,250 or less to 3,000 mg/day may reduce phosphorus levels in patients with chronic kidney disease (CKD) and hyperphosphatemia.

Study: Phosphate Binder Noncompliance Underreported

By

NATIONAL HARBOR, Md.—Dialysis patient underreporting of noncompliance with phosphate binder therapy may contribute to poor phosphorus control, investigators reported at the National Kidney Foundation 2012 Spring Clinical Meetings.

Novel Iron-Based Phosphate Binder Effective, Well-Tolerated

By

NATIONAL HARBOR, Md.—An investigational iron-based phosphate binder is effective and well tolerated in hemodialysis (HD) patients with hyperphosphatemia, according to data presented at the National Kidney Foundation 2012 Spring Clinical Meetings.

Novel Binder Lowers Phosphorus, LDL Cholesterol

By

An investigational calcium-free phosphate binder called colestilan is safe and effective for controlling phosphorus in dialysis patients, and it has no impact on calcium levels, researchers reported.

Phosphate-Binder Choice Could Impact Missed Dialysis Sessions

By

Use of sevelamer rather than calcium-based calcium binders (CBBs) to treat hyperphosphatemia in dialysis patients is associated with a reduction in missed in-center dialysis treatments regardless of dialysis organization size, according to findings published in abstract form as part of Renal Week 2010 in Denver.

Sign Up for Free e-newsletters